Compare VERU & ZDGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | ZDGE |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 41.5M |
| IPO Year | 1996 | 2016 |
| Metric | VERU | ZDGE |
|---|---|---|
| Price | $2.62 | $3.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 65.5K | 55.0K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | N/A | ★ 73.85 |
| EPS | N/A | ★ 0.06 |
| Revenue | $16,296,958.00 | ★ $29,398,000.00 |
| Revenue This Year | N/A | $3.27 |
| Revenue Next Year | N/A | $5.76 |
| P/E Ratio | ★ N/A | $51.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $1.73 |
| 52 Week High | $4.59 | $4.70 |
| Indicator | VERU | ZDGE |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 48.85 |
| Support Level | $2.15 | $2.94 |
| Resistance Level | $2.77 | $3.44 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 79.17 | 47.06 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.